Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (1875)	9/6/2007 12:16:27 AM
From: Jibacoa	Respond to of 3722

Jason, I haven't been paying much attention to the market lately. I decided to raise cash, took profits at the start of the market's correction early last month & still am on a wait & see mode.(The losses I had taken care of long before.<g>) Re: GILD The stock was able to hold on Aug29 above the 35 level. It didn't test the Mar14 L at 34.15(adjusted for the 2x1 split) bigcharts.marketwatch.com It had found resistance at the 42 level (from Apr24 to June5)& started on a near term downtrend on Jun7 in spite of persistent double digit improvements on revenues & earnings. The EE for 2007 are still expected to be 20% better than in 2006.Its ROE remains > 30%. The FDA granted approval of Letairis for PAH in June. On its 2ndQ it reported higher sales of Atripla and Truvada. It has good institutional sponsors with Fidelity's Magellan & Contrafund owning >1B each, as well as Barclays, Janus, etc. finance.yahoo.com The stock had a very good,steady run from its adjusted L of 3.11 on January 2001 to its May 23 H of 42.23 bigcharts.marketwatch.com It seems that it should hold somewhere above the $30 to $35 level, but I would rather wait for confirmation. ( I wouldn't mind paying a few dollars more & buying it" on the way up" , after it is off from its present near term DT.) bigcharts.marketwatch.com Bernard

To: tnsaf who wrote (1875)	10/2/2007 12:35:07 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

GILD Has recovered from its Aug dip. bigcharts.marketwatch.com But is finding today some resistance at the 42 level bigcharts.marketwatch.com It has resistance at that level from its May- June Hs bigcharts.marketwatch.com The stock should be able to go through that resistance with the help of the coming meeting of the American Association for the Study of Liver Diseases, in Boston on Nov 2-6, for which some abstracts are now becoming available. GS 9190 showed a median viral load reduction of 0.5 to 1.5 log, depending on the dosage, which is considered a good level of efficacy & there wasn't any evidence of major toxicity. That's is the result of a "single dose". The data from the PI showing results after 8 days is expected to be presented at the Nov meeting. On Sep 24 GILD also announced that data from a PIIb of darusentan, DAR-201 for treatment of resistant hypertension, were published in the Oct edition of the Jrn. Clin Hyp. On that PIIb darusentan was evaluated as an add-on antihypertensive in patients who had not achieved goal blood pressure while treated with full doses of 3 or more medications, including a diuretic. GILD is now conducting 2 PIIIs in patients with resistant hypertension. In the preliminary study results, darusentan was shown to be effective at lowering blood pressure as add-on therapy in hypertensive patients classified as resistant. It seems that GILD shouldn't have much problem in resuming its long term UT.<g> bigcharts.marketwatch.com Bernard